Search hospitals
>
Indiana
>
Indianapolis
Indiana University/Melvin and Bren Simon Cancer Center
Claim this profile
Indianapolis, Indiana 46202
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Ovarian Cancer
Conducts research for Pancreatic Cancer
917 reported clinical trials
43 medical researchers
Summary
Indiana University/Melvin and Bren Simon Cancer Center is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer and other specialties. Indiana University/Melvin and Bren Simon Cancer Center is involved with conducting 917 clinical trials across 619 conditions. There are 43 research doctors associated with this hospital, such as Kathy Miller, MD, Nabil Adra, MD, Shadia Jalal, MD, and Anita Turk, MD.
Area of expertise
Breast Cancer
Indiana University/Melvin and Bren Simon Cancer Center has run 129 trials for Breast Cancer. Some of their research focus areas include:
Cancer
Indiana University/Melvin and Bren Simon Cancer Center has run 93 trials for Cancer. Some of their research focus areas include:
Top PIs
Kathy Miller, MD
Indiana University/Melvin and Bren Simon Cancer Center
9 years of reported clinical research
Nabil Adra, MD
Indiana University Melvin and Bren Simon Cancer Center
5 years of reported clinical research
Shadia Jalal, MD
Indiana University/Melvin and Bren Simon Cancer Center
1 year of reported clinical research
Anita Turk, MD
IU Health North Hospital
6 years of reported clinical research
Clinical Trials running at Indiana University/Melvin and Bren Simon Cancer Center
Breast Cancer
Lung Cancer
Cancer
Skin Cancer
Small Cell Lung Cancer
Multiple Myeloma
Breast cancer
Ovarian Cancer
Prostate Cancer
Testicular cancer
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting
2 awards
Phase 3
8 criteria
HER2-Targeted Therapy
for Breast Cancer
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Recruiting
2 awards
Phase 3
5 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting
2 awards
Phase 3
47 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Indiana University/Melvin and Bren Simon Cancer Center?
Indiana University/Melvin and Bren Simon Cancer Center is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer and other specialties. Indiana University/Melvin and Bren Simon Cancer Center is involved with conducting 917 clinical trials across 619 conditions. There are 43 research doctors associated with this hospital, such as Kathy Miller, MD, Nabil Adra, MD, Shadia Jalal, MD, and Anita Turk, MD.
Where is Indiana University/Melvin and Bren Simon Cancer Center located?
The Indiana University Melvin and Bren Simon Cancer Center is located at 980 W. Walnut St., Indianapolis, IN 46202. It is situated near the intersection of West Walnut Street and Senate Avenue, within the IU Health campus in downtown Indianapolis.
Who should I call to ask about financial aid or insurance network?
**Indiana University/Melvin and Bren Simon Cancer Center Financial Assistance:** - **Phone:** (877) 846-3448 - **Website:** [IU Health Financial Assistance](https://www.indianadisabilityresourcefinder.org/view/provider/2646/iu-health-financial-assistance) **Insurance Department:** - **Website:** [Contact Information](https://cancer.iu.edu/contact/index.html) For additional support, refer to the IU Cancer Support Resource Guide for Indiana University Employees.
What insurance does Indiana University/Melvin and Bren Simon Cancer Center accept?
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center, located in Indianapolis, Indiana, is Indiana's only National Cancer Institute-designated comprehensive cancer center. It offers a multidisciplinary approach to patient care, combining treatment, research, and supportive care tailored to individual needs. The center is recognized for its significant contributions to cancer research, including over 700 adult and pediatric clinical trials, and its commitment to improving patient outcomes through innovative therapies and comprehensive care programs like the CompleteLife Program.
What awards or recognition has Indiana University/Melvin and Bren Simon Cancer Center received?
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center is Indiana's only National Cancer Institute-designated comprehensive cancer center, a distinction that represents the highest level of recognition from the National Cancer Institute. It has earned international acclaim for its pioneering clinical and novel cancer research, supported by nearly 250 dedicated researchers. Through a partnership with IU Health, Indiana's largest health system, the center's physician-scientists extend their expertise across the state, influencing care at all 16 IU Health hospitals.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.